2013
DOI: 10.1016/s0924-8579(13)70252-8
|View full text |Cite
|
Sign up to set email alerts
|

P7 Efficacy of antifungal therapy with inhaled azole against murine invasive pulmonary aspergillosis with ITCZ-low susceptible Aspergillus fumigatus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…McConville et al demonstrated previously that single-dose nebulized itraconazole maintained high concentrations in the lung in mice for more than 24 h ( 18 ), and this was also demonstrated in rats ( 19 ). Furthermore, the survival rates of the group of mice receiving nebulized itraconazole were significantly higher than those of the group of mice receiving oral itraconazole administration ( 20 ). Since those reports, new formulations of itraconazole for topical treatment, such as nanoparticles ( 21 , 22 ), polymeric micelles ( 23 ), itraconazole-loaded nanostructured lipid carriers ( 24 ), and dry powder ( 25 ), have been developed, although the in vivo antifungal activities of these inhaled products have not been reported formally.…”
Section: Introductionmentioning
confidence: 83%
“…McConville et al demonstrated previously that single-dose nebulized itraconazole maintained high concentrations in the lung in mice for more than 24 h ( 18 ), and this was also demonstrated in rats ( 19 ). Furthermore, the survival rates of the group of mice receiving nebulized itraconazole were significantly higher than those of the group of mice receiving oral itraconazole administration ( 20 ). Since those reports, new formulations of itraconazole for topical treatment, such as nanoparticles ( 21 , 22 ), polymeric micelles ( 23 ), itraconazole-loaded nanostructured lipid carriers ( 24 ), and dry powder ( 25 ), have been developed, although the in vivo antifungal activities of these inhaled products have not been reported formally.…”
Section: Introductionmentioning
confidence: 83%
“…demonstrated that a single dose of nebulised itraconazole maintained high concentrations in lung in mice for more than 24 hours and it has also been demonstrated in rats . Furthermore the survival rates of the group of mice receiving nebulised itraconazole were significantly higher than the group of mice receiving oral itraconazole administration . Posaconazole, the most potent triazole, has longer tissue retention than itraconazole or voriconazole, but topical treatment of posaconazole, as a potential option for the treatment, has not been tested in vivo.…”
Section: Introductionmentioning
confidence: 99%